SNC-103 is under clinical development by Shanghai Simnova Biotechnology and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin Lymphoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SNC-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Shanghai Simnova Biotechnology overview
Shanghai Simnova Biotechnology is a clinical cell therapy platform company. It is headquartered in Shanghai, China.
For a complete picture of SNC-103’s drug-specific PTSR and LoA scores, buy the report here.